CD274 and lung carcinoma: Function-blocking antibodies such as anti-PD-1 and anti-PDL-1, which disrupt the interaction of immune checkpoints on the surface of T cells and their cognate ligands on tumor cells, have shown considerable efficacy in the clinic against a number of cancers including melanomas, renal cancer and lung cancer [30–33].